Receipt: https://pmc.ncbi.nlm.nih.gov/articles/PMC8747183/ Read: 2026-11-12, curl with browser user agent, HTML converted to text, HTTP 200 Note: Review: evidence that NAD+ falls with age is limited, especially in humans. (Text converted from HTML; the superscript plus in NAD+ is joined to the word.) --- Abstract Nicotinamide adenine dinucleotide (NAD+) is an essential molecule involved in various metabolic reactions, acting as an electron donor in the electron transport chain and as a co-factor for NAD+-dependent enzymes. In the early 2000s, reports that NAD+ declines with aging introduced the notion that NAD+ metabolism is globally and progressively impaired with age. Since then, NAD+ became an attractive target for potential pharmacological therapies aiming to increase NAD+ levels to promote vitality and protect against age-related diseases. This review summarizes and discusses a collection of studies that report the levels of NAD+ with aging in different species (i.e., yeast, C. elegans , rat, mouse, monkey, and human), to determine whether the notion that overall NAD+ levels decrease with aging stands true. We find that, despite systematic claims of overall changes in NAD+ levels with aging, the evidence to support such claims is very limited and often restricted to a single tissue or cell type. This is particularly true in humans, where the development of NAD+ levels during aging is still poorly characterized. There is a need for much larger, preferably longitudinal, studies to assess how NAD+ levels develop with aging in various tissues. This will strengthen our conclusions on NAD metabolism during aging and should provide a foundation for better pharmacological targeting of relevant tissues. Keywords: NAD+ , aging, yeast, C. elegans , mouse, rat, monkey, human 1. Introduction Nicotinamide adenine dinucleotide (NAD+) can be generated from tryptophan or micronutrient precursors from the Vitamin B 3 family, which consist of nicotinamide (NAM), nicotinic acid (NA), and nicotinamide riboside (NR). NAD+ precursors are micronutrients naturally found in the diet and can be obtained from different vegetal and animal food sources, found in high levels in, for example, cucumber, cabbage, soybeans, broccoli, avocado, tomato, whole wheat, yeast, eggs, milk, meat, and liver. NAD+ is an important cofactor for adenosine triphosphate (ATP) production in glycolysis and oxidative phosphorylation as well as in cellular redox reactions by oxidoreductase enzymes [ 1 ]. NAD+ also functions as an essential co-substrate in pathways that regulate a wide variety of cellular processes such as DNA repair [ 2 ], cellular senescence [ 3 , 4 ], and mitochondrial respiratory function [ 5 ]. Consistent with its pleiotropic roles, NAD+ is a tightly regulated molecule, the levels of which are maintained through a fine balance between producing and consuming processes [ 6 ]. NAD+ is synthesized through distinct pathways in mammalian cells, including the following pathways ( Figure 1 ): the kynurenine pathway, the Preiss–Handler pathway, and the salvage pathway. The kynurenine pathway involves the conversion of tryptophan into 2-amino-3-carboxymuconate semialdehyde (ACMS) via indoleamine-2,3-dioxygenase/tryptophan-2,3-dioxygenase (IDO/TDO). Through a spontaneous reaction, ACMS can be converted into quinolinic acid (QA) and subsequently into nicotinic acid mononucleotide (NAMN) via quinolinic acid phosphoribosyltransferase (QPRT) [ 7 ]. This NAD+ synthesis pathway is particularly important in the liver [ 8 ] and in macrophages [ 9 ]. Figure 1. Open in a new tab NAD+ biosynthesis pathways in mammalian cells. ACMS: 2-amino-3-carboxymuconate, NA: nicotinic acid, NAD+ : nicotinamide adenine dinucleotide, NAM: nicotinamide, NAMN: nicotinic acid mononucleotide, NAR: nicoti [...] nd protect against age-related diseases. This review summarizes and discusses a collection of studies that report the levels of NAD+ with aging in different species (i.e., yeast, C. elegans , rat, mouse, monkey, and human), to determine whether the notion that overall NAD+ levels decrease with aging stands true. We find that, despite systematic claims of overall changes in NAD+ levels with aging, the evidence to support such claims is very limited and often restricted to a single tissue or cell type. This is particularly true in humans, where the development of NAD+ levels during aging is still poorly characterized. There is a need for much larger, preferably longitudinal, studies to assess how NAD+ levels develop with aging in various tissues. This will strengthen our conclusions on NAD metabolism during aging and should provide a foundation for better pharmacological targeting of relevant tissues. Keywords: NAD+ , aging, yeast, C. elegans , mouse, rat, monkey, human 1. Introduction Nicotinamide adenine dinucleotide (NAD+) can be generated from tryptophan or micronutrient precursors from the Vitamin B 3 f [...]